REACTINE® Complete Sinus + Allergy
Relief of symptoms (includes sneezing, rhinorrhea, post nasal discharge, tearing and redness of the eyes and nasal congestion) associated with seasonal and perennial allergic rhinitis.
Temporarily relieves the symptoms of seasonal and perennial allergic rhinitis:
Runny nose
Post nasal discharge
Sneezing
Tearing and redness of the eyes
Nasal congestion
Active Ingredients (in each tablet):
Cetirizine HCl 5 mg (Antihistamine)
Pseudoephedrine HCI 120 mg (Sympathomimetic Amine)
Inactive Ingredients:
Croscarmellose sodium, hypromellose, lactose, magnesium, stearate, microcrystalline cellulose, polyethylene glycol, silicon dioxide, titanium dioxide
Directions
Tablets should be swallowed with liquid (with or without food), and should not be divided, chewed, or crushed.
Adults and children 12 years and over
Take 1 tablet every 12 hours
Adults 65 years of age and over
In patients with moderate hepatic and/or renal impairment, a dose of 1 tablet daily is recommended
Severe skin reactions such as generalized exanthematous pustulosis (AGEP) have been reported very rarely with cetirizine-containing products. This may exhibit an early or delayed onset with numerous small, mostly non-follicular pustules on the skin. Patients should be carefully monitored. Patients should discontinue use and consult a physician if symptoms persist, worsen, or if new symptoms occur.
Sympathomimetics should be used with caution in patients with stenosing peptic ulcer, pyloroduodenal obstruction, prostatic hypertrophy, or bladder neck obstruction, cardiovascular disease, arrhythmia, tachycardia, hypertension, hyperthyroidism, increased intraocular pressure, renal or hepatic insufficiency or diabetes mellitus. Sympathomimetics should be used with caution in patients receiving decongestants, appetite suppressants, psychostimulants (i.e., amphetamines), tricyclic antidepressants, and digitalis.
REACTINE® COMPLETE is contraindicated in patients who have a known hypersensitivity to cetirizine, to its parent compound, hydroxyzine, to piperazine derivatives, those with a known hypersensitivity or idiosyncrasy to pseudoephedrine hydrochloride, to adrenergic agents, to other drugs of similar chemical structures, or to any of the ingredients in the formulation or components of the container.
Due to its pseudoephedrine hydrochloride component, REACTINE® COMPLETE is contraindicated in patients with narrow-angle glaucoma or urinary retention, and in patients receiving monoamine oxidase (MAO) inhibitory therapy or within 14 days of stopping such treatment. It is also contraindicated in patients with severe hypertension, or severe coronary artery disease, and in patients with hyperthyroidism.
If drowsiness occurs, patients should be advised to not drive or operate machinery and to avoid concurrent of use of REACTINE® COMPLETE with sedating substances such as alcohol and other medications including: anti-anxiety medications, sleep aids, antihistamines, antidepressants, muscle relaxants, or prescription analgesics.
The most common side effects associated with REACTINE® COMPLETE (Cetirizine Hydrocholoride and Pseudoephedrine Hydrochloride Extended-Release Tablets) are headache (7.42%), somnolence (9.63%) and dry mouth (2.09%).
There are no adequate and well-controlled studies in pregnant women. Until such data become available, REACTINE® COMPLETE should not be used during pregnancy, unless advised otherwise by a physician.
Cetirizine has been reported to be excreted in human milk. For pseudoephedrine hydrochloride administered alone, about 0.5% of the dose has been reported to be excreted in human breast milk. Because cetirizine and pseudoephedrine are excreted in milk, use of REACTINE® COMPLETE in nursing mothers is not recommended.
Overdose has been reported with REACTINE® COMPLETE. For management of a suspected overdose, patients should contact their regional Poison Control Centre.
Store between 15° to 30°C.
Questions? Call 1-87-REACTINE (1-877-322-8463).
This website contains current product information and may differ from the information on the product packaging you may have. If you have any questions, please contact 1-87-REACTINE (1-877-322-8463).
Please consult the Product Monograph at:
https://pdf.hres.ca/dpd_pm/00074077.PDF for important information on contraindications, warning, precautions, adverse reactions, interactions, and dosing information, which has not been discussed in this piece.
The Product Monograph is also available by calling our medical information department at 1-87-REACTINE.
